Pfizer/Merck KGAA's Bavencio Fails OS Endpoint In Second-Line Lung Cancer
The firms still hope to produce positive data in first-line non-small cell lung cancer in 2019, but Bavencio is falling well behind its checkpoint inhibitor competition.
You may also be interested in...
Lessons learned about blinding and stratification from Pfizer and Merck KGaA’s earlier Phase III disappointment shaped the design of BeyondSpring's ongoing Phase III trial of plinabulin in second- and third-line non-small cell lung cancer.
PD-1/L1 inhibitors are eagerly awaited in ovarian cancer, but the combination of Bavencio with chemotherapy doesn't work well in platinum-resistant disease.
Study of PD-L1/TKI combo succeeded in an all comers population across risk groups, which could be differentiating, for a while.